Furthermore, TP53 mutations seldom co‐occur with alterations in the RAS pathway (4%), FLT3 (6%), NPM1 (8%), or single‐nucleotide variants in recurrent AML‐associated genes such as (DNMT3A, TET2, IDH1/2) [81, 82]. The gene discussed is TP53; the disease is acute myeloid leukemia.